This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Allessandra DiCorato January 14, 2025 Credit: Maria Nemchuk, Broad Communications Eric Minikel and Sonia Vallabh run a lab with a singular focus: preventing and treating prion disease within their lifetime. Its a huge privilege to have the opportunity to point these powerful new tools at our disease.
Tests, in mice, of a drug developed by the researchers showed that regulatory T cells can be attracted to specific body parts, boosted in number, and activated to suppress immune response and rebuild tissue. Clinical trials in humans are now planned.
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research points to a novel -- and noble -- approach: using Xenon gas. A phase 1 clinical trial of the treatment in healthy volunteers will begin in early 2025.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
But its impact goes far beyond research. From Research to Real-World Care 🌎 Understand how AI-driven advancements are shaping personalized treatments and patient outcomes. Navigating the AI Landscape 🤖 Explore the opportunities and challenges with integrating AI in healthcare and disease prevention.
By Count Me In Communications March 11, 2025 Count Me In , a patient-partnered research initiative led by the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute, is launching a new project focused on translocation renal cell carcinoma (tRCC), a rare and aggressive form of kidney cancer.
a new Italian incubator dedicated to the discovery and development of small molecule-based treatments for neurodegenerative diseases, announced today that it has adopted Collaborative Drug Discovery’s CDD Vault as its platform of choice for managing drug discovery data.
THURSDAY, April 11, 2024 -- The discovery of a gene variant that rids the brain of toxic plaques linked to Alzheimer's might lead to new treatments for the disease, researchers report.The variant arises naturally in people who don't seem to get.
Researchers have identified a 'guard mechanism' for a protein which attacks microbes in infected cells, opening the possibility of new treatments for Toxoplasma, Chlamydia, Tuberculosis and even cancer.
Researchers map communities of single cells in metastatic breast cancers By Corie Lok October 30, 2024 Breadcrumb Home Researchers map communities of single cells in metastatic breast cancers The team compared different single-cell and spatial profiling methods to explore the diversity of cells in metastatic breast cancer biopsies.
It's an achievement with important implications for scientists studying the brain and working on treatments for a broad range of neurological and neurodevelopmental disorders, such as Alzheimer's and Parkinson's disease.
19, 2024 -- Parkinson's is a relentless disease for which few treatments, and no real cure, exists. Now, researchers say they are on the trail of a potential new therapy for the disabling neurological illness.It's early research. THURSDAY, Dec.
However, new research suggests that a less aggressive approach to treating the disease has helped an increasing. MONDAY, Feb. 5, 2024 -- Rectal cancer often involves surgeries that can lead to a debilitating loss of bowel function for patients.
A gene encoding a protein linked to tau production -- tripartite motif protein 11 (TRIM11) -- was found to suppress deterioration in small animal models of neurodegenerative diseases similar to Alzheimer's disease (AD), while improving cognitive and motor abilities, according to new research.
23, 2024 -- Two new strategies using deep brain stimulation can improve symptoms of Parkinson’s disease, Duke University researchers have found.Doctors can efficiently improve symptoms of Parkinson’s by simultaneously targeting to. TUESDAY, Jan.
Researchers have achieved a significant breakthrough in identifying the primary cause and potential treatment for preeclampsia, a severe pregnancy complication. Upon testing this antibody in mice, the researchers found the all symptoms associated with preeclampsia were corrected.
The Swiss pharma company is the latest large drugmaker to invest big in an experimental heart treatment, after years of prioritizing medicines for cancer and immune diseases.
Scribe will receive $40 million upfront from Sanofi in a collaboration initially focused on developing an in vivo gene editing treatment for sickle cell disease.
The figure depicts the neuroprotective role of exendin-4 in Alzheimer's disease and Parkinson's disease. Exendin-4's diverse therapeutic targets suggest its potential therapeutic uses in neurodegenerative ailments like Alzheimer's disease and Parkinson's disease and have garnered an increasing amount of attention.
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
Researchers have discovered that mutations affect protein stability following remarkably simple rules. The discovery has profound implications for accelerating the development of new treatments for diseases or the design of new proteins with industrial applications.
New research shows that the heart has a mini-brain -- its own nervous system that controls the heartbeat. A better understanding of this system, which is much more diverse and complex than previously thought, could lead to new treatments for heart diseases.
In two studies, researchers have now conducted a detailed study of the microbiome, i.e. the totality of all microorganisms, in humans and zoo animals. The aim was to identify starting points for strategies for the treatment and diagnosis of diseases.
Researchers in Japan found a positive turnaround in markers of gum well-being after people with. MONDAY, Sept. 23, 2024 -- Diabetes can worsen the state of your gums, but a new study suggests that diabetes medications may undo some of that damage.
Almost every one of us will know someone with a neurodegenerative disease such as Alzheimer’s or Parkinson’s. It is less common to know someone with a rare genetic disease; but while individually rare, collectively they have an enormous impact. Most of these conditions are genetic in origin and the majority have no effective treatment.
Using an animal model of multiple sclerosis (MS), researchers have created a four-dimensional brain map that reveals how lesions similar to those seen in human MS form. These findings provide a window into the early disease state and could help identify potential targets for MS treatments and brain tissue repair.
Neurons were classified by software as either positive for prion protein expression (yellow) before treatment with CHARM (left panel), or negative (purple) after treatment (right panel). Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms.
New research for the first time reveals the function of a little-understood junction between cells in the brain that could have important treatment implications for conditions ranging from multiple sclerosis to Alzheimer's disease, to a type of brain cancer known as glioma.
A new gene therapy treatment for Duchenne muscular dystrophy (DMD) shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in the future, repairing those muscles.
Imagine being able to create an in vitro replica of a diseased organ to study the molecular mechanism underlying the illness. Now take a step further: envision testing drugs in these organoids to identify the ones that can treat disease safely and effectively without needing to run expensive clinical trials first.
Their work focuses on creating ‘digital twin generators’ – AI-driven models that predict how a patients disease may progress over time. AI-powered digital twins A key component of Unlearns work is its focus on digital twin technology, which uses AI to create personalised models of disease progression for individual patients.
MONDAY, May 20, 2024 -- Women treated for infertility were twice as likely as those who conceived naturally to be hospitalized with heart disease within a year of delivery, recent research shows.They are particularly likely to land in the hospital.
It is the first time researchers use data from protein shapes and combine it with data from genomic sequences to improve the reliability of evolutionary trees, a critical resource used by the scientific community for understanding the history of life, monitor the spread of pathogens or create new treatments for disease.
This collaboration has the potential not only to accelerate our understanding of the diseases, but also potentially enable scientific advancements in disease-modifying interventions — a true game changer in addressing cardiometabolic diseases.” The collaboration will focus on advancing three programs over the next three years.
By Lucy Mutz November 4, 2024 Credit: Juliana Sohn Kasper Lage is managing director of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease. The overall goal is to translate genetic findings into biological mechanisms underlying disease that could be targeted with new medicines.
The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. The integration of AI in drug discovery is revolutionizing the way researchers approach the development of new treatments for various diseases. Traditional.
Researchers have discovered a new type of neuron that plays a fundamental role in recognition memory -- how the brain registers the difference between new and familiar objects and forms long-term memories. The new cell type, called ovoid cells, are found in the hippocampus of mice, humans and other mammals.
ABSTRACT Parkinson's disease (PD) is the second most common neurodegenerative disease but has limited medications. Targeting leucine-rich repeat kinase 2 (LRRK2) has been identified as a potential strategy for the treatment of PD.
The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. Schwamborns research focuses on creating patient-specific brain organoids.
They found significant associations between the thinning of different retinal layers and increased risk of developing ocular, cardiac, pulmonary, metabolic, and neuropsychiatric diseases and identified genes that are associated with retinal layer thickness. Their findings are published in Science Translational Medicine. “We
Neuropsychiatric treatment is on the verge of a major transformation. Historically, treatment options have been limited, with patients relying on daily medications that have minimal efficacy and troublesome side effects. “Zelquistinel is a positive modulator of NMDA receptors,” Donello explains.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content